Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody

Journal of Immunology

Volumn 167, Issue 6, 2001, Pages 3201-3206

  Pilon, S A ^a   Piechocki, M P ^a   Wei, W Z ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; DNA VACCINE ERBB 2; DNA VACCINE ERBB 2 TARGETED TO THE CYTOPLASM; DNA VACCINE TYROSINE KINASE DEFICIENT CYTE2; DNA VACCINE TYROSINE KINASE DEFICIENT ERBB 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2 DERIVATIVE; PROTEASOME; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; EFFECTOR CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR GROWTH; VACCINATION;

EID: 0035885171     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.6.3201     Document Type: Article

References (29)

1. Increased erbB-2 gene copies and expression in multiple stages of breast cancer
2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
3. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
4. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
5. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer
6. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
7. + cytotoxic T lymphocytes
8. Cardiotoxicity in patients receiving Trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact?
9. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake
10. B cells inhibit induction of T cell-dependent tumor immunity
11. Immunological enhancement: A study of blocking antibodies
12. DNA vaccines encoding full-length or truncated neu induce protective immunity against neu-expressing mammary tumors
13. Inhibition of carcinogenesis by DNA vaccination
14. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
15. Successful immunization of rhesus monkeys with the extracellular domain of p185HER2: A potential approach to human breast cancer
16. + tumors
17. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self protein
18. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA
19. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation
20. FACS quantitation of leucine aminopeptidase and acid phosphatase on tumor associated macrophages from metastatic and nonmetastatic mouse mammary tumors
21. T helper I (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching
22. Distinct role of antigen-specific T helper type I (Th1) and Th2 cells in tumor eradication in vivo
23. Nonclinical studies addressing the mechanism of action of Trastuzumab (Herceptin)
24. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine
25. erbB2 binds to GRP94 in vivo
26. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules
27. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2
28. Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interaction of neu receptors with coated pits
29. Role of antigen-presenting cells in mediating tolerance and autoimmunity